sinc
end
increas
number
case
pneumonia
report
wuhan
follow
citi
provinc
china
mani
countri
novel
coronaviru
sever
acut
respiratori
syndrom
coronaviru
new
human
pathogen
identifi
caus
wuhan
pneumonia
diseas
spectrum
infect
socal
coronaviru
diseas
covid
known
divers
sever
rang
asymptomat
carriag
mild
respiratori
tract
infect
sever
fatal
pneumonia
moreov
transmit
within
famili
commun
among
cruis
passeng
hospit
becom
publichealth
emerg
intern
concern
pheic
declar
world
health
organ
januari
februari
laboratoryconfirm
case
report
countri
territori
case
report
global
case
report
china
http
wwwworldometersinfocoronaviru
view
virologist
human
zoonot
coronavirus
belong
famili
coronavirida
order
nidoviral
current
four
genera
subfamili
coronavirina
famili
coronavirida
alphacoronaviru
betacoronaviru
deltacoronaviru
gammacoronaviru
current
epidem
six
recognis
human
respiratori
coronavirus
includ
alphacoronaviru
betacoronaviru
alphacoronaviru
betacoronaviru
often
caus
mild
respiratori
tract
infect
well
sarscov
merscov
contrast
lead
sever
even
fatal
lower
respiratori
tract
diseas
seventh
human
coronaviru
belong
genu
betacoronaviru
also
contain
sarscov
merscov
far
drug
monoclon
antibodi
vaccin
approv
treat
human
infect
due
coronavirus
sever
preexist
potenti
drug
candid
includ
chloroquin
remdesivir
consid
discoveri
market
new
compound
often
requir
month
year
howev
face
global
spread
effect
intervent
sever
case
urgent
requir
although
littl
known
sever
insight
may
jid
antag
march
gain
wellknown
famili
member
sarscov
review
literatur
exist
approv
antivir
agent
remdesivir
exhibit
promis
vitro
antivir
activ
preliminari
clinic
experi
treatment
although
sarscov
share
rna
sequenc
ident
rnadepend
rna
polymeras
rdrp
share
sequenc
ident
therefor
drug
target
viral
rdrp
protein
sarscov
like
effect
rdrp
target
genu
betacoronaviru
sever
potenti
drug
compound
includ
favipiravir
ribavirin
penciclovir
galidesivir
remdesivir
fluorin
aristeromycin
analogu
acyclovir
flexim
analogu
remdesivir
phosphoramid
prodrug
adenosin
cnucleosid
similar
structur
tenofovir
alafenamid
nucleotid
analogu
adenosin
antivir
activ
hepat
b
viru
human
immunodefici
viru
hiv
develop
gilead
scienc
inc
licens
approv
anywher
far
moreov
recommend
treatment
cat
felin
infecti
periton
uncommon
fatal
caus
felin
coronaviru
chemic
formula
remdesivir
molecular
mass
c
h
n
p
remdesivir
effect
metabolis
activ
nucleosid
triphosph
sever
human
cell
line
vitro
studi
demonstr
nucleosid
triphosph
work
incorpor
competitor
adenosin
triphosph
confus
viral
rdrp
act
delay
rna
chain
termin
ebola
viru
evad
proofread
viral
exoribonucleas
caus
decreas
viral
rna
product
recent
antivir
activ
remdesivir
demonstr
stage
viru
entri
vero
cell
support
antivir
mechan
nucleotid
analogu
remdesivir
report
activ
ebola
viru
multipl
human
cell
type
includ
primari
macrophag
human
endotheli
cell
low
halfmaxim
effect
concentr
ec
valu
addit
remdesivir
report
exhibit
antivir
activ
vitro
marburg
viru
paramyxovirida
parainfluenza
type
viru
nipah
viru
hendra
viru
measl
mump
virus
pneumovirida
respiratori
syncyti
viru
primari
human
airway
epitheli
cell
cultur
biolog
relev
vitro
model
pulmonari
infect
remdesivir
shown
inhibit
sarscov
halfmaxim
inhibitori
concentr
ic
merscov
ic
replic
addit
remdesivir
effect
mani
human
zoonot
coronavirus
includ
mous
hepat
viru
mhv
betacoronaviru
sarscov
relat
bat
coronavirus
betacoronaviru
merscov
relat
bat
coronaviru
porcin
deltacoronaviru
deltacoronaviru
recent
studi
report
vitro
antivir
activ
remdesivir
caus
aetiolog
pathogen
wuhan
pneumonia
ec
remdesivir
vero
cell
ec
therefor
remdesivir
regard
broadspectrum
anticoronaviru
activ
even
approv
clinic
use
concern
antivir
resist
remdesivir
studi
use
mhv
test
coronaviru
two
three
lineag
wildtyp
mhv
presenc
increas
concentr
lost
repeat
passag
one
lineag
passag
select
lowlevel
resist
mutant
confer
increas
ec
two
amino
acid
substitut
note
nonstructur
protein
nsp
rdrp
mhv
also
result
increas
ec
sarscov
howev
remdesivirresist
mhv
mutat
outcompet
wildtyp
mhv
absenc
suggest
effect
remdesivir
resist
decreas
viral
fit
note
mous
model
sarscov
infect
remdesivirresist
sarscovinfect
mice
lost
less
weight
evid
declin
pulmonari
viral
load
day
infect
wildtyp
sarscovinfect
mice
indic
attenu
pathogen
remdesivirresist
sarscov
find
indic
high
genet
barrier
remdesivir
develop
resist
well
decreas
fit
pathogen
remdesivirresist
mutant
encourag
therapeut
potenti
remdesivir
treatment
newli
emerg
favour
vitro
antivir
activ
remdesivir
test
anim
model
differ
viral
infect
rhesu
monkey
model
ebola
viru
diseas
daili
administr
mgkg
remdesivir
day
profoundli
suppress
replic
ebola
viru
protect
infect
anim
lethal
infect
besid
mous
model
sarscov
infect
prophylact
earli
therapeut
dose
remdesivir
effect
decreas
viral
load
lung
improv
pulmonari
function
accord
previou
rhesu
monkey
model
ebola
viru
infect
intraven
iv
mgkg
dose
remdesivir
could
lead
last
level
activ
triphosph
form
peripher
blood
mononuclear
cell
pbmc
least
h
data
may
valuabl
anim
speci
infect
although
anim
studi
plasma
halflif
remdesivir
short
h
remdesivir
rapidli
distribut
pbmc
convert
activ
form
within
h
postinfus
intracellular
halflif
h
absenc
human
pharmacokinet
inform
data
rhesu
monkey
indic
parenter
daili
dose
remdesivir
may
achiev
sustain
intracellular
concentr
nucleotid
triphosph
ec
vitro
anim
data
provid
preliminari
evid
support
clinic
potenti
remdesivir
human
infect
caus
contemporari
emerg
coronavirus
includ
earli
clinic
experi
remdesivir
therapi
femal
nurs
scotland
ebola
meningoenceph
support
detect
ebola
viru
rna
plasma
cerebrospin
fluid
first
use
ebola
viru
infect
human
report
success
treat
highdos
corticosteroid
day
remdesivir
therapi
oncedaili
infus
mg
h
day
daili
mg
anoth
day
seriou
clinic
biochem
event
occur
except
transient
rise
serum
amylas
level
recent
publish
randomis
control
clinic
trial
four
experiment
therapeut
ebola
viru
diseas
total
patient
ever
receiv
remdesivir
although
remdesivir
therapi
favour
due
high
mortal
rate
detail
clinic
biochem
side
effect
associ
remdesivir
therapi
ever
describ
safeti
profil
jid
antag
march
remdesivir
challeng
one
patient
remdesivir
therapi
develop
hypotens
cardiac
arrest
discontinu
load
dose
howev
author
explain
advers
event
exclud
relat
underli
ebola
viru
diseas
potenti
fatal
infecti
diseas
first
case
washington
usa
compassion
treat
iv
remdesivir
progress
pneumonia
day
hospitalis
interestingli
patient
condit
improv
obviou
advers
effect
observ
note
realtim
revers
transcript
pcr
test
nasopharyng
oropharyng
swab
remain
posit
day
administr
remdesivir
author
note
trend
declin
viral
load
nasopharyng
swab
cycl
threshold
valu
ill
day
day
remdesivir
administr
day
day
oropharyng
swab
test
neg
one
day
later
cours
earli
conclud
direct
antivir
effect
remdesivir
enhanc
clear
viral
load
respiratori
tract
inde
suggest
promis
therapeut
effect
remdesivir
two
phase
randomis
doubleblind
placebocontrol
multicentr
clinic
trial
current
ongo
china
trial
submit
clinicaltrialsgov
januari
design
evalu
efficaci
safeti
parenter
remdesivir
hospitalis
adult
mildtomoder
sever
ie
http
clinicaltrialsgov
http
clinicaltri
respect
number
case
plan
enrol
respect
regimen
remdesivir
treatment
follow
mg
load
dose
day
follow
mg
oncedaili
mainten
dose
day
studi
former
regimen
remdesivir
therapi
use
randomis
clinic
trial
ebola
viru
diseas
effect
reduct
pulmonari
viral
load
murin
model
sarscov
infect
potent
antivir
activ
accept
safeti
profil
parenter
remdesivir
therapi
two
case
report
randomis
trial
ebola
viru
diseas
clinic
use
remdesivir
case
highli
anticip
two
randomis
clinic
trial
parenter
remdesivir
therapi
treatment
covid
china
may
open
window
effect
antivir
therapi
epidem
infecti
diseas
fund
none
